CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
hysteroscopic ablation of submucous uterine fibroid using diode laserdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05604001
NCT05604001N/ACompleted
CompareCT.gov

In-office Hysteroscopic Laser Ablation for Symptomatic Submucous Uterine Fibroids: Impact on Size and Vascularization.

Ariel University·interventional·Posted Nov 3, 2022·Updated Jul 24, 2023

In Brief

A clinical study evaluating hysteroscopic ablation of submucous uterine fibroid using diode laser for Laser Hysteroscopic Ablation of Submucous Myoma. Completed, enrolled 20 participants across 4 sites in 3 countries.

Detailed Summary

To evaluate feasibility and efficacy of in-office hysteroscopic ablation of submucous uterine fibroid using diode laser

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLaser Hysteroscopic Ablation of Submucous Myoma
CountriesIsrael, Italy, Spain
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 3, 2022
Enrollment StartJan 1, 2018
Primary CompletionJan 30, 2019
Study CompletionDec 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.7 years ago

Interventions

hysteroscopic ablation of submucous uterine fibroid using diode laserdevice

patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy and laser ablation of the myoma